192 related articles for article (PubMed ID: 30607746)
1. Evaluation of expression of somatostatin receptor 1, 2, 3, 5 and dopamine D2 receptor in spindle cell oncocytomas of posterior pituitary.
Soukup J; Kasparova P; Kohout A; Rychly B; Skarkova V; Syrucek M; Gabalec F
Pituitary; 2019 Feb; 22(1):70-78. PubMed ID: 30607746
[TBL] [Abstract][Full Text] [Related]
2. Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas.
Saveanu A; Jaquet P; Brue T; Barlier A
Mol Cell Endocrinol; 2008 May; 286(1-2):206-13. PubMed ID: 18241980
[TBL] [Abstract][Full Text] [Related]
3. [New medical treatments in pituitary adenomas].
Drutel A; Caron P; Archambeaud F
Ann Endocrinol (Paris); 2008 Sep; 69 Suppl 1():S16-28. PubMed ID: 18954854
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin receptor subtypes sst1, sst2, sst3 and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography.
Schaer JC; Waser B; Mengod G; Reubi JC
Int J Cancer; 1997 Mar; 70(5):530-7. PubMed ID: 9052751
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of filamin A in patients with acromegaly and its association with somatostatin and dopamine receptor profiles.
Coelho MCA; Vasquez ML; Wildemberg LE; Vázquez-Borrego MC; Bitana L; Camacho AHDS; Silva D; Ogino LL; Ventura N; Sánchez-Sánchez R; Chimelli L; Kasuki L; Luque RM; Gadelha MR
Sci Rep; 2019 Feb; 9(1):1122. PubMed ID: 30718563
[TBL] [Abstract][Full Text] [Related]
6. The effect of selective sst1, sst2, sst5 somatostatin receptors agonists, a somatostatin/dopamine (SST/DA) chimera and bromocriptine on the "clinically non-functioning" pituitary adenomas in vitro.
Gruszka A; Kunert-Radek J; Radek A; Pisarek H; Taylor J; Dong JZ; Culler MD; Pawlikowski M
Life Sci; 2006 Jan; 78(7):689-93. PubMed ID: 16115652
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas.
Saveanu A; Gunz G; Guillen S; Dufour H; Culler MD; Jaquet P
Neuroendocrinology; 2006; 83(3-4):258-63. PubMed ID: 17047391
[TBL] [Abstract][Full Text] [Related]
8. Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study.
Bertherat J; Tenenbaum F; Perlemoine K; Videau C; Alberini JL; Richard B; Dousset B; Bertagna X; Epelbaum J
J Clin Endocrinol Metab; 2003 Nov; 88(11):5353-60. PubMed ID: 14602773
[TBL] [Abstract][Full Text] [Related]
9. Effects of somatostatin-14 and the receptor-specific somatostatin analogs on chromogranin A and alpha-subunit (alpha-SU) release from "clinically nonfunctioning" pituitary adenoma cells incubated in vitro.
Pawlikowski M; Lawnicka H; Pisarek H; Kunert-Radek J; Radek M; Culler MD
J Physiol Pharmacol; 2007 Mar; 58(1):179-88. PubMed ID: 17440235
[TBL] [Abstract][Full Text] [Related]
10. Expression and localisation of somatostatin receptor subtypes sst1-sst5 in areas of the rat medulla oblongata involved in autonomic regulation.
Spary EJ; Maqbool A; Batten TF
J Chem Neuroanat; 2008 Jan; 35(1):49-66. PubMed ID: 17646081
[TBL] [Abstract][Full Text] [Related]
11. Pituitary somatostatin receptor (sst)1-5 expression during rat development: age-dependent expression of sst2.
Reed DK; Korytko AI; Hipkin RW; Wehrenberg WB; Schonbrunn A; Cuttler L
Endocrinology; 1999 Oct; 140(10):4739-44. PubMed ID: 10499533
[TBL] [Abstract][Full Text] [Related]
12. Modulation of pituitary somatostatin receptor subtype (sst1-5) messenger ribonucleic acid levels by changes in the growth hormone axis.
Park S; Kamegai J; Johnson TA; Frohman LA; Kineman RD
Endocrinology; 2000 Oct; 141(10):3556-63. PubMed ID: 11014208
[TBL] [Abstract][Full Text] [Related]
13. A Critical Evaluation of sst3 and sst5 Immunohistochemistry in Human Pituitary Adenomas.
Körner M; Waser B; Christ E; Beck J; Reubi JC
Neuroendocrinology; 2018; 106(2):116-127. PubMed ID: 28384628
[TBL] [Abstract][Full Text] [Related]
14. Research Resource: Real-Time Analysis of Somatostatin and Dopamine Receptor Signaling in Pituitary Cells Using a Fluorescence-Based Membrane Potential Assay.
Günther T; Culler M; Schulz S
Mol Endocrinol; 2016 Apr; 30(4):479-90. PubMed ID: 26967369
[TBL] [Abstract][Full Text] [Related]
15. Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro.
Zatelli MC; Piccin D; Tagliati F; Bottoni A; Ambrosio MR; Margutti A; Scanarini M; Bondanelli M; Culler MD; degli Uberti EC
J Mol Endocrinol; 2005 Oct; 35(2):333-41. PubMed ID: 16216913
[TBL] [Abstract][Full Text] [Related]
16. Selective regulation of somatostatin receptor subtype signaling: evidence for constitutive receptor activation.
Ben-Shlomo A; Pichurin O; Barshop NJ; Wawrowsky KA; Taylor J; Culler MD; Chesnokova V; Liu NA; Melmed S
Mol Endocrinol; 2007 Oct; 21(10):2565-78. PubMed ID: 17609435
[TBL] [Abstract][Full Text] [Related]
17. Role of glucocorticoids in the regulation of pituitary somatostatin receptor subtype (sst1-sst5) mRNA levels: evidence for direct and somatostatin-mediated effects.
Park S; Kamegai J; Kineman RD
Neuroendocrinology; 2003 Sep; 78(3):163-75. PubMed ID: 14512709
[TBL] [Abstract][Full Text] [Related]
18. Drug design at peptide receptors: somatostatin receptor ligands.
Hannon JP; Nunn C; Stolz B; Bruns C; Weckbecker G; Lewis I; Troxler T; Hurth K; Hoyer D
J Mol Neurosci; 2002; 18(1-2):15-27. PubMed ID: 11931345
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin receptors and their subtypes in human tumors and in peritumoral vessels.
Reubi JC; Schaer JC; Laissue JA; Waser B
Metabolism; 1996 Aug; 45(8 Suppl 1):39-41. PubMed ID: 8769377
[TBL] [Abstract][Full Text] [Related]
20. Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists.
Cescato R; Schulz S; Waser B; Eltschinger V; Rivier JE; Wester HJ; Culler M; Ginj M; Liu Q; Schonbrunn A; Reubi JC
J Nucl Med; 2006 Mar; 47(3):502-11. PubMed ID: 16513620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
